Zijie Tang

Dr. Zijie Tang

Department of Dermatology, The First Center of the General Hospital of the People's Liberation Army, Beijing, China, Beijing, China
orcid
Post-Doctorate. Dermatologist

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2024 in Journal of Dermatological Treatment
Verified
Journal Article
Open access
RWRui Wang
Rui Wang
CYChongli Yu
Chongli Yu
ZTZijie Tang
Zijie Tang
JSJie Sun
Jie Sun
YWYoulin Wang
Youlin Wang
CLChengxin Li
Chengxin Li
Background: Psoriatic patients tend to develop metabolic syndrome (MS). MS accelerates psoriasis, but the exact molecular mechanisms are poorly understood.Objectives: We aim to investigate the impact of leptin on keratinocyte insulin sensitivity and explore its underlying molecular mechanism, which might play a role in the pathogenesis of this disease.Methods: ELISA and immunohistochemistry were applied respectively to detect the level of leptin in serum and in lesion of psoriatic patients with and without MS. The HaCaT cell line was cultured and western-blot assay was performed to assess the change of insulin sensibility. q-PCR and western-blot assay were applied to detect the SOCS3 expressions. Knockdown of SOCS3 were generated in HaCaT cell line by siRNA. Leptin and insulin were treated for 6 days and K10 expression was evaluated by western-blot assay.Results: Patients with MS had higher level of leptin in serum and lesions than their counterparts without MS. Serum levels of leptin was negatively correlated to PASI decline index in psoriatic patients. Long-term treatment of leptin induced insulin resistance in HaCaT cell line, as indicated by elevated expression of p-IRS-1 (ser636) and lower p-PKB (ser473). Leptin treatment up-regulated the mRNA and protein expression of SOCS3. Knockdown of SOCS3 blocked the effect of leptin-induced insulin resistance. Leptin treatment attenuated insulin-elicited K10 expression.Conclusions: Leptin induces insulin resistance by upregulating SOCS3 and give rise to differentiation disorder of keratinocyte. Insulin resistance may serve as a target for anti-psoriatic therapies.

1 February 2024 in Clinical, Cosmetic and Investigational Dermatology
Verified
Journal Article
Open access
PDF file
ZTZijie Tang
Zijie Tang
JYJing-Run Yang
Jing-Run Yang
CYChong-Li Yu
Chong-Li Yu
MDMei-Han Dong
Mei-Han Dong
RWRui Wang
Rui Wang
CLCheng-Xin Li
Cheng-Xin Li
Background: Psoriasis is a frequent form of chronic inflammation in dermatology that is unmistakably linked to the metabolic syndrome (MetS) and its elements. This study was to explore the current status and new developments in the global research, and the holistic landscape of this field more intuitively through bibliometric analysis of scientific output and activity. Methods: Publications regarding psoriasis and MetS were searched and chosen from the database of the Web of Science Core Collection. Excel 2019, VOSviewer, and CiteSpace software were utilized to conduct bibliometric analysis. Results: There were 1096 publications included. The scientific outputs in this field had increased from 2004 to 2022, and the expansion could continue in the following years. The United States contributed the most publications (241, 21.99%) and had the most citation frequency (13,489 times). The University of California System was the most productive affiliation. Girolomoni G., Armstrong A.W., Gisondi P. and Gelfand J.M. were key and influential researchers. Journal of the European Academy of Dermatology and Venereology published the greatest number of articles (65 articles). By analyzing keyword frequency and clustering, we have identified the following areas of research interest and frontiers: prevalence, risk, association, gene expression, waist circumference, adipose tissue inflammation, vascular inflammation, cardiovascular disease, psoriatic arthritis, and fibrosis. Conclusion: This bibliometric analysis elucidates research domain of psoriasis and MetS, portraying present hotspots and future emerging trends. This field has generated significant interest and displays potential for further growth. The United States has made distinguished contributions, and currently dominates this field.

1 January 2026 in Journal of Immunology Research
Verified
Journal Article
Open access
ZTZijie Tang
Zijie Tang
JWJintong Wu
Jintong Wu
MDMeihan Dong
Meihan Dong
CLChengxin Li
Chengxin Li
RWRui Wang
Rui Wang
Psoriasis is a chronic, immune‐mediated inflammatory disease with systemic manifestations that include renal complications. Immunoglobulin A nephropathy (IgAN) represents the most common autoimmune glomerular disease worldwide. Growing epidemiological and genetic evidence supports a clinically relevant association between psoriasis and IgAN, particularly in patients with moderate‐to‐severe or arthropathic psoriasis. However, current knowledge remains limited by heterogeneous observational data and the absence of systematic renal screening in most psoriasis clinical trials. This review synthesizes evidence linking psoriasis and IgAN across multiple levels. Mendelian randomization studies point to a shared genetic basis, and transcriptomic analyses have uncovered overlapping immune signatures. Several inflammatory pathways may drive the production of galactose‐deficient IgA1 (Gd‐IgA1) and facilitate glomerular immune complex deposition. Aberrant IgA1 glycosylation driven by psoriatic inflammation, together with tonsillar immune activation, is proposed as a key connection between skin and kidney disease. Important knowledge gaps persist. Routine urinalysis is not performed in most psoriasis trials. Tonsillectomy data derive largely from East Asian populations, and no large‐scale international registries are currently available. We therefore propose a clinical screening framework and advocate for the establishment of dedicated registries, along with the integration of urinary tests into future trials. Addressing these gaps will enable mechanism‐based, personalized management of psoriasis‐associated IgAN.

5 May 2025 in Mycopathologia
Verified
Journal Article
Closed access
PDF file
JWJintong Wu
Jintong Wu
ZTZijie Tang
Zijie Tang
SWSu Wang
Su Wang
YQYuxin Qiu
Yuxin Qiu
XNXinyu Nie
Xinyu Nie
RWRui Wang
Rui Wang

1 May 2026 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
ZTZijie Tang
Zijie Tang
JWJintong Wu
Jintong Wu
MDMeihan Dong
Meihan Dong
CLChengxin Li
Chengxin Li
RWRui Wang
Rui Wang
Psoriasis is a common chronic inflammatory skin disorder frequently accompanied by multisystem involvement, with increasing concern regarding its association with renal impairment. The advent and widespread use of biologic agents in the treatment of moderate to severe psoriasis have transformed therapeutic strategies, yet their effects on renal function and the underlying mechanisms remain a critical area of investigation. This review synthesizes current clinical and experimental evidence on the renal impact of biologics used in psoriasis management, focusing on the safety profiles of different biologic classes and their roles in modulating kidney-related complications. We explore how immune regulation, inflammation suppression, and cell death pathways contribute to both renal protection and injury, highlighting the influence of tumor necrosis factor (TNF)-α inhibitors, interleukin (IL) -17 and IL-12/23 inhibitors. By integrating recent clinical studies and basic research findings, this article aims to provide clinicians with a theoretical basis for the rational selection of biologic therapies in psoriasis patients with renal concerns and to stimulate further research into optimizing treatment strategies that safeguard kidney health.

1 October 2025
Verified
Journal Article
Closed access
MDMeihan Dong
Meihan Dong
RWRui Wang
Rui Wang
ZTZijie Tang
Zijie Tang
CLChengxin Li
Chengxin Li